Article Details

Can China sustain a surge in oncology drug innovation? | PharmaVoice

Retrieved on: 2025-07-02 13:34:16

Tags for this article:

Click the tags to see associated articles and topics

Can China sustain a surge in oncology drug innovation? | PharmaVoice. View article details on hiswai:

Excerpt

Chinese drugs account for 51% of antibody-drug conjugates in development, 48% of bispecific monoclonal antibodies and 48% of CAR-T therapies ...

Article found on: www.pharmavoice.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo